Envestnet Asset Management’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Envestnet Asset Management’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$319K	Sell	8,340 -9,258	-53%	-$322K	﹤0.01%	4387
2026 Q1	$605K	Sell	17,598 -716	-4%	-$24.5K	﹤0.01%	3797
2025 Q4	$603K	Buy	18,314 +182	+1%	+$5.67K	﹤0.01%	3574
2025 Q3	$517K	Buy	18,132 +367	+2%	+$9.98K	﹤0.01%	3736
2025 Q2	$455K	Sell	17,765 -1,034	-6%	-$26.2K	﹤0.01%	3763
2025 Q1	$517K	Buy	18,799 +2,396	+15%	+$66.4K	﹤0.01%	3600
2024 Q4	$442K	Buy	16,403 +2,384	+17%	+$66.9K	﹤0.01%	3648
2024 Q3	$404K	Buy	+14,019	New	+$401K	﹤0.01%	3650
2022 Q2	–	Sell	-20,230	Closed	-$538K	–	3964
2022 Q1	$538K	Buy	+20,230	New	+$522K	﹤0.01%	3083

Other funds holding FTXH

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

MIM

Marshall Investment Management Littleton, Colorado $241M AUM 30.53% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.75B AUM 46.53% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Nilsine Partners Greenwood Village, Colorado $1.45B AUM 47.06% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management's FTXH Position: Q2 2026 in Review

Envestnet Asset Management reduced its First Trust Nasdaq Pharmaceuticals ETF (FTXH) stake by 53% in Q2 2026, selling an estimated $322K and leaving 8,340 shares worth $319K. The position accounts for ﹤0.01% of the portfolio, ranked #4387.

Envestnet Asset Management first reported a position in FTXH in Q1 2022 and has held it in 9 quarters since. The position peaked at $605K in Q1 2026. 30 funds tracked by Wall St. Rank hold FTXH as of Q2 2026.

Envestnet Asset Management held 8,340 shares of First Trust Nasdaq Pharmaceuticals ETF worth $319K as of Q2 2026.
Envestnet Asset Management sold 9,258 First Trust Nasdaq Pharmaceuticals ETF shares in Q2 2026, an estimated $322K.
First Trust Nasdaq Pharmaceuticals ETF made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #4387 holding.
Envestnet Asset Management first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q1 2022 and has held it in 9 quarters since.
Envestnet Asset Management's First Trust Nasdaq Pharmaceuticals ETF position peaked at $605K in Q1 2026.
30 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.